Gilead Trodelvy® Significantly Improved Quality of Life Over Standard of Care

 Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In addition to the previously reported overall survival benefit observed with Trodelvy compared with chemotherapy chosen by patients’ physicians (11.8 months vs. 6.9 months; HR: 0.51; 95% CI: 0.41-0.62; p<0.0001), this new sub-analysis demonstrated significant and clinically meaningful improvements in health-related quality of life (HRQoL) with Trodelvy. The results were presented at the European Society of Medical Oncology (ESMO) Congress 2021 from September 16-21, 2021 (Poster #257P).

https://www.businesswire.com/news/home/20210916005029/en/Trodelvy%C2%AE-Significantly-Improved-Quality-of-Life-Over-Standard-of-Care-in-2L-Metastatic-Triple-Negative-Breast-Cancer-in-Phase-3-ASCENT-Study